PrecisionUTR
Engineered for Therapeutic Performance
PrecisionUTR™ is NovoVessel’s proprietary mRNA optimization platform designed to enhance translation efficiency and improve tissue-selective expression for next-generation therapeutic applications.
5’UTR
Optimized for efficient translation initiation
3’UTR
Optimized for stability and controlled expression
HOW IT WORKS
PrecisionUTR™ is built on deep understanding of mRNA biology and sequence-structure-function relationships.
SEQUENCE ENGINEERING
Proprietary design of 5’ and 3’ UTRs to optimize mRNA performance.
ENHANCED TRANSLATION
Improved initiation and translation drive higher protein expression.
TISSUE SELECTIVITY
Engineered UTRs promote expression in target tissues and reduce off-target activity.
THERAPEUTIC EFFICIENCY
Greater potency with the potential for lower dosing requirements.
PLATFORM BENEFITS
ENHANCED TRANSLATION
Up to 6x higher protein expression in preclinical studies.*
TISSUE SELECTIVITY
Improved on-target expression with off-target activity.*
DOSE EFFICIENCY
Potential to achieve therapeutic effect with significantly lower doses.*
*Preclinical data. Results may vary depending on the molecule, target and delivery approach.
DESIGNED FOR BROAD APPLICATIONS
PrecisionUTR™ is a versatile platform with the potential to enhance the performance of a wide range of mRNA therapeutics.
Cardiovascular Diseases
Rare Diseases
Regenerative Medicine
Neurological Disorders
Oncology
Gene & Protein Replacement
Metabolic Disorders
Rewriting the Rules of mRNA Therapeutics
PrecisionUTR™ is our foundation for building the next generation of mRNA medicines with greater precision, potency and potential.
Let’s build better mRNA therapies, together.